(Q26825970)

Barbara L. Asselin

series ordinal

2

1 reference

Paul V. Plourde

series ordinal

3

1 reference

Tim Corn

series ordinal

4

1 reference

language of work or name

1 reference

November 2014

1 reference

Annals of the New York Academy of Sciences

published in

1 reference

volume

1329

1 reference

page(s)

81-92

1 reference

Modern therapy of acute lymphoblastic leukemia

cites work

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

New definition of remission in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. II. Lymphoma 6C3HED cells cultured in a medium devoid of L-asparagine lose their susceptibility to the effects of guinea pig serum in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Suppression of murine leukemias by L-asparaginase. Incidence of sensitivity among leukemias of various types: comparative inhibitory activities of guinea pig serum L-asparaginase and Escherichia coli L-asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Two L-asparaginases from E. coli and their action against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

L-Asparaginase in Treatment of Acute Leukaemia and Lymphosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Toxicity of E. coli L-asparaginase in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Immunological responses to L-asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institut

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Evidence that the L-Asparaginase Activity of Guinea Pig Serum is responsible for its Antilymphoma Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Immunosuppression by L-Asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

L-asparaginase therapy in children with advanced leukemia. The Southwest Cancer Chemotherapy Study Group

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Therapy with Erwinia L-asparaginase in children with acute leukemia after anaphylaxis to E. coli L-asparaginase

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

TUMOR INHIBITORY EFFECT OF L-ASPARAGINASE FROM ESCHERICHIA COLI

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

A new L-asparaginase with antitumour activity?

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Two L-asparaginases from Escherichia coli B. Their separation, purification, and antitumor activity

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Asparaginase and Glutaminase Activities of Bacteria

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Minimal residual disease in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Comparative pharmacokinetic studies of three asparaginase preparations

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01.

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021

Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12496

7 January 2021